The Cytel blog keeps you up to speed with the latest developments in biostatistics and clinical biometrics.
One of the revelations of the COVID-19 pandemic is that the flexibility and potential of Bayesian designs goes far beyond the benefits connected to informed priors. Rather a number of other benefits to Bayesian designs are sometimes under-appreciated. The importance of using Bayesian methods to choose composite endpoints, for example, particularly in longitudinal studies, can be overlooked when considering Bayesian and Frequentist options.
Cytel statisticians reflected on these benefits during a recent panel discussion.